99
99
Mar 22, 2013
03/13
by
CNBC
tv
eye 99
favorite 0
quote 0
amgen is. new all-time high today. >> booikers? >> well, what b.k. thinks is that next week we might get that last rally. one thing the news this week told you is that domestic u.s. is the play to buy. buy iwm, domestic companies in the u.s. >> let's move on here. russia rebuffing cyprus's request for aid. will this derail the rally and will cyprus leave the eu? for more, let's bring in the president and chief investment officer of merck investments. great to speak with you. >> great to be with you. >> we saw a fairly big move in the euro today. i'm wondering what you think is going to unfold next week. >> well, you guys pointed out, bernanke's all that matters. there is somebody on the other side of that trade, the european central bank. the europeans have been mopping up liquidity. the americans, the brits, the japanese, all printing money like crazy. i disagree with the notion that they will always fix it and that's why the market is up. is market is up even if cyprus were to melt down. what people have realized is that cyprus is not contagious. w
amgen is. new all-time high today. >> booikers? >> well, what b.k. thinks is that next week we might get that last rally. one thing the news this week told you is that domestic u.s. is the play to buy. buy iwm, domestic companies in the u.s. >> let's move on here. russia rebuffing cyprus's request for aid. will this derail the rally and will cyprus leave the eu? for more, let's bring in the president and chief investment officer of merck investments. great to speak with you....
107
107
Mar 29, 2013
03/13
by
CNBC
tv
eye 107
favorite 0
quote 0
you saw amgen, biogen, gilead, hitting all time highs. i was long amgen, i sold it this week. that's a big move for -- >> the leadership has been from health care? >> what concerns me -- >> staples in terms of stocks. >> what concerns me more than the price action is the fact that earnings, earnings going forward are actually not going to be that strong, and we've seen that from fedex, from oracle, but also if you look at some of the more cyclical sectors globally such as materials and energy, we haven't seen the strength. >> hi there. >> hi. >> there are a few things i like to live by. >> such as? >> you don't fight land wars in asia, people learn that the hard way. you don't get takeout food on a monday, especially after a holiday. >> why not? >> it's all the leftover garbage. >> okay. >> -- a doorway. >> or that. >> how about something that pertains to this show. >> the market doesn't give you this, and i say it all the time. the market doesn't give you this long to sell the top, which is why we're going to continue to ground higher. i'm in the beaks camp. i'm in his camp.
you saw amgen, biogen, gilead, hitting all time highs. i was long amgen, i sold it this week. that's a big move for -- >> the leadership has been from health care? >> what concerns me -- >> staples in terms of stocks. >> what concerns me more than the price action is the fact that earnings, earnings going forward are actually not going to be that strong, and we've seen that from fedex, from oracle, but also if you look at some of the more cyclical sectors globally such...
516
516
Mar 28, 2013
03/13
by
CNBC
tv
eye 516
favorite 0
quote 0
anyway, now regarding the amgens and biogens and health care in general. >> right. >> caller: as the scientist, it seems obvious to me that classic big old pharma is out and cutting edge biotech is the future. so who, what, when how is the best way to play? and thanks and kudos on our eight years. >> well, you are terrific to say those kind words about me and our staff is fabulous and thank you. i'm agreeing with you entirely. that's why i like celgene, biogen. look, i've got to tell you, i think regeneron is really great, gilead, amgen's great, we didn't make the cut, didn't have fast enough growth. it was more like old line pharma. all right. i think it is time right now to -- to ride the innovation wave in biotechs. this week, look at this, these are all the companies that are making the big initiatives. you should have one of these. not just the income-producing drug stocks, which, by the way, you know i like too. and regeneron may be the fastest grower of all. don't move, "lightning round" is coming up next. [ male announcer ] i've seen incredible things. otherworldly things. bu
anyway, now regarding the amgens and biogens and health care in general. >> right. >> caller: as the scientist, it seems obvious to me that classic big old pharma is out and cutting edge biotech is the future. so who, what, when how is the best way to play? and thanks and kudos on our eight years. >> well, you are terrific to say those kind words about me and our staff is fabulous and thank you. i'm agreeing with you entirely. that's why i like celgene, biogen. look, i've got...
113
113
Mar 29, 2013
03/13
by
CNBC
tv
eye 113
favorite 0
quote 0
look, i've got to tell you, i think regeneron is really great, gilead, amgen's great, we didn't make the cut, didn't have fast enough growth. it was more like old line pharma. all right. i think it is time right now to ride the innovation wave in biotechs. this week, look at this, these are all the companies that are making the big initiatives. you should have one of these. not just the income-producing drug stocks, which, by the way, you know i like too. and regeneron may be the fastest grower of all. don't move, "lightning round" is coming up next. stamps.com is the best. i don't have to leave my desk and get up and go to the post office anymore. [ male announcer ] with stamps.com you can print real u.s. postage for all your letters and packages. i have exactly the amount of postage i need, the instant i need it. can you print only stamps? no... first class. priority mail. certified. international. and the mail man picks it up. i don't leave the shop anymore. [ male announcer ] get a 4 week trial plus $100 in extras including postage and a digital scale. go to stamps.com/tv and nev
look, i've got to tell you, i think regeneron is really great, gilead, amgen's great, we didn't make the cut, didn't have fast enough growth. it was more like old line pharma. all right. i think it is time right now to ride the innovation wave in biotechs. this week, look at this, these are all the companies that are making the big initiatives. you should have one of these. not just the income-producing drug stocks, which, by the way, you know i like too. and regeneron may be the fastest grower...
90
90
Mar 20, 2013
03/13
by
CNBC
tv
eye 90
favorite 0
quote 0
i'd much rather own like i mentioned at the top of the show an amgen or abbott labs or merck.ing a 10, 12 valuation. >> i eel take the other side. i think it's a great name because of the stable growth. over the last five years. although you're going to pay a premium because it's a premium name because of the dividend and the number they're putting up you own general mills here. >> my problem right now is the fact that their margins are going down. i think it's priced to perfection. great stock, well managed. they're doing everything they can. but i think they have priced themselves perfectly. i would wait for a pull back. >> corn and wheat prices have come in though. if they stay in, i don't believe they will, and hopefully the guys are putting on some hedges that's their business. putting on the hedges for the inputs, wheat, corn, rice the rest of it. i think general mills is a good do here, but it's scary. >> sounds like we're split. interesting, again. cramer will have the ceo on tonight. finally ebay says it will overhaul fees for sellers in a bid to step up competition w
i'd much rather own like i mentioned at the top of the show an amgen or abbott labs or merck.ing a 10, 12 valuation. >> i eel take the other side. i think it's a great name because of the stable growth. over the last five years. although you're going to pay a premium because it's a premium name because of the dividend and the number they're putting up you own general mills here. >> my problem right now is the fact that their margins are going down. i think it's priced to perfection....
177
177
Mar 28, 2013
03/13
by
KQED
tv
eye 177
favorite 0
quote 0
and the amgen foundation. additional support provided by -- the william k. bowes, jr. foundation. anne s. bowers, the robert noyce trust. the dirk and charlene kabcenell foundation. and the vadasz family foundation. support is also provided by -- >>> there was a time, not that long ago, when people felt that the playing field was level. back then, the only way to enhance your body was to combine discipline and hard work. but as the pursuit of human peak performance strays further into bioscience, technology is calling into question the very nature of what we mean by human potential. craig cisar is a professor of kinesiology at san jose state.
and the amgen foundation. additional support provided by -- the william k. bowes, jr. foundation. anne s. bowers, the robert noyce trust. the dirk and charlene kabcenell foundation. and the vadasz family foundation. support is also provided by -- >>> there was a time, not that long ago, when people felt that the playing field was level. back then, the only way to enhance your body was to combine discipline and hard work. but as the pursuit of human peak performance strays further into...
286
286
Mar 29, 2013
03/13
by
CNBC
tv
eye 286
favorite 0
quote 0
look, i've got to tell you, i think regeneron is really great, gilead, amgen's great, we didn't make the cut, didn't have fast enough growth. it was more like old line pharma. all right. i think it is time right now to ride the innovation wave in biotechs. this week, look at this, these are all the companies that are making the big initiatives. you should have one of these. not just the income-producing drug stocks, which, by the way, you know i like too. and regeneron may be the fastest grower of all. don't move, "lightning round" is coming up next. [singing] hoveround takes me where i wanna go... where will it send me... one call to hoveround and you'll be singing too! pick up the phone and call hoveround, the premier power chair. hoveround makes it easier than any other power chair. hoveround is more maneuverable to get you through the tightest doors and hallways. more reliable. hoveround employees build your chair, deliver your chair, and will service your chair for as long as you own your chair. most importantly, 9 out of 10 people got their hoveround for little or no cost. call
look, i've got to tell you, i think regeneron is really great, gilead, amgen's great, we didn't make the cut, didn't have fast enough growth. it was more like old line pharma. all right. i think it is time right now to ride the innovation wave in biotechs. this week, look at this, these are all the companies that are making the big initiatives. you should have one of these. not just the income-producing drug stocks, which, by the way, you know i like too. and regeneron may be the fastest grower...
140
140
Mar 27, 2013
03/13
by
KQED
tv
eye 140
favorite 0
quote 0
bristol-myers squibb leading the way up almost 25% year to date, followed by eli lilly, pfizer, amgen and merck. >>> it is set to become one of the ten largest shareholders in goldman sachs. the move comes as goldman gives berkshire millions of shares in place of warrants dating back to the depths of the financial crisis and that's when buffett came to the rescue of the wall street firm by investing $5 billion. goldmaniay stock was closing at their 146. at that price berkshire would receive 9.5 million shares. netflix was the biggest gainer in the s&p 500 today after an analyst boosted the company's price target to $225. he says the company's streaming video business has the potential of drawing in more subscribers. netflix shares have doubled this year and they rose today to $190 and that's a gain of 5.5%. >> a historic hearing on the u.s. supreme court on whether same-sex couples would have time to rally. john harwood joins us from the supreme court in washington. what did the justices hear today? >> the two-day sense of argument on same-sex marriage. tonight it was about ate, ban g
bristol-myers squibb leading the way up almost 25% year to date, followed by eli lilly, pfizer, amgen and merck. >>> it is set to become one of the ten largest shareholders in goldman sachs. the move comes as goldman gives berkshire millions of shares in place of warrants dating back to the depths of the financial crisis and that's when buffett came to the rescue of the wall street firm by investing $5 billion. goldmaniay stock was closing at their 146. at that price berkshire would...
186
186
Mar 23, 2013
03/13
by
CSPAN
tv
eye 186
favorite 0
quote 0
would take a hit. -- investors''s' amgen talked about the fact that they would take a hit. ,his wasut in by two senators orrin hatch and max baucus. this is the kind of thing that happens in congress fairly frequently. there are all these details and small bits of language and it is hard to unfurl what is going on. it is the kind of thing the ethics committee would be looking at, members of congress benefiting one company with legislation. this never ends up within the purview of the ethics committee. congress who of have been disciplined in the house of representatives. there have been 23 centers -- 10 reprimands. bill allison, before we get back to the calls, tell us what the sunlight foundation is and what you do. is tryingt foundation to make government more transparent. we begin with a focus on congress. we have spread out and we are looking at state legislatures. we have a site that makes all state bills much more sensible and easier for the public access and follow. we have a policy department that pushes for greater transparency in congress around the country. we look at int
would take a hit. -- investors''s' amgen talked about the fact that they would take a hit. ,his wasut in by two senators orrin hatch and max baucus. this is the kind of thing that happens in congress fairly frequently. there are all these details and small bits of language and it is hard to unfurl what is going on. it is the kind of thing the ethics committee would be looking at, members of congress benefiting one company with legislation. this never ends up within the purview of the ethics...
110
110
Mar 25, 2013
03/13
by
FBC
tv
eye 110
favorite 0
quote 0
amgen, another all-time high, at 96.89. another all-time high. we're off the lows of the session. we had been down 117 points. i'm heading this way to david asman. david: it has been a long time, girl. j&j is interesting story. in addition to everything else being very, very good working stock right now, it still still gives out the dividend, well over 3%. people keep wondering how high the market can go as long as you get dividends and no place else to put your money you put it in the stock market. nicole petallides. it really started when we heard the official from europe saying perhaps cyprus would be a model for other countries if they have banking problems? >> that's right. when you start it hear that maybe they would seize assets or confiscate money in other countries it putting a little fear and contagion in there. what we saw was the euro dropped to a 4-month low. the lowest level since september 22nd. our markets that were in the green turned into the red. liz: it is around 1.28 at the moment. as we show s&p losers, we should talk about best buy not a loser at all. in fac
amgen, another all-time high, at 96.89. another all-time high. we're off the lows of the session. we had been down 117 points. i'm heading this way to david asman. david: it has been a long time, girl. j&j is interesting story. in addition to everything else being very, very good working stock right now, it still still gives out the dividend, well over 3%. people keep wondering how high the market can go as long as you get dividends and no place else to put your money you put it in the...
143
143
Mar 26, 2013
03/13
by
CNBC
tv
eye 143
favorite 0
quote 0
almost almost half a percent or just about seven points n terms of stocks, include american express and amgenth solid gains of about a percent to a percent and change. bob pisani is here on the floor of the nyse with some of the trading action. so yesterday we were down triple digits, today up triple digits. >> with the s&p up seven points, dow up 70, you would think we would have all the market leaders, but the tone is fairly defensive. utilities moving up, consumer staples, all market leaders, the finances are really the laggard here. tech is also not as strong as the overall market. no sign of pulling out of bonds. this story is going no where are. bond etfs have had inflows four straight days, including some of the corporate bond etfs. four straight days to the upside. retail stocks have been a bit weak today, so noticeable declines. gap, chico's and american eagle, look at those declines here. i think this is related to the consumer confidence number. put up the retail etf, you can buy all of these stocks in a single etf, you see how it dropped right after 10:00. i think that is the prob
almost almost half a percent or just about seven points n terms of stocks, include american express and amgenth solid gains of about a percent to a percent and change. bob pisani is here on the floor of the nyse with some of the trading action. so yesterday we were down triple digits, today up triple digits. >> with the s&p up seven points, dow up 70, you would think we would have all the market leaders, but the tone is fairly defensive. utilities moving up, consumer staples, all...
182
182
Mar 1, 2013
03/13
by
CNBC
tv
eye 182
favorite 0
quote 0
finally let's recap the week in nasdaq, leaders include regeneron pharmaceuticals and amgen, laggardsf5, sears, intuitive and apple, now a 52-week low, now down some 32% from its 2008 peek. >> josh, thanks very much. >> we're in the finley stretch. we've got about 45 minutes before the "closing bell" sounds today. a complete reversal earlier. we are, we need to close up 110 points to hit an all-time high. >> that would be nice, but i don't think so today, right? not happening. we're digging in for gold. she's not going to answer my question. we're digging for gold. the precious metal getting crushed lately. can you buy on the dip with gold and come out on top, he asks. that's coming up. >>> and then after the break, find out where barclays sees opportunity and don't miss my exclusive interknew with the barclays president. that's coming up. back in a moment. how do traders using technical analysis streamline their process? at fidelity, we do it by merging two tools into one. combining your customized charts with leading-edge analysis tools from recognia so you can quickly spot key tren
finally let's recap the week in nasdaq, leaders include regeneron pharmaceuticals and amgen, laggardsf5, sears, intuitive and apple, now a 52-week low, now down some 32% from its 2008 peek. >> josh, thanks very much. >> we're in the finley stretch. we've got about 45 minutes before the "closing bell" sounds today. a complete reversal earlier. we are, we need to close up 110 points to hit an all-time high. >> that would be nice, but i don't think so today, right? not...
118
118
Mar 7, 2013
03/13
by
CNBC
tv
eye 118
favorite 0
quote 0
amgen, great free flow of cash, unbelievable. i like what they're doing right now.far as they've got a great pipeline. a lot of people don't understand that. you look at the trading in a forward p/e of 11, it's very attractive. i look at disney in the same manner, when i look at the management, strong, trades at a fair p/e. if it were to pullback on any kind of a big move in the market and then, of course, i'm always pounding the table on these financials. jpmorgan, that's the standout, the xlf, people are coming for it, coming for jpmorgan if we pull back, that name's going higher. >> since mid november, financials the best performing s&p sector up more than 20%. and pete, you're convinced it has more to go. >> if there were a pullback, i'd want to pile into more. i've been in this name almost consistently for the entire run. i've been thinking and pounding the table we're going to 50. i think 55's on the table. >> mike murphy, the market's not going to go up forever. it's going to pull back. >> i think one of the first names i would look at is goldman sachs. goldm
amgen, great free flow of cash, unbelievable. i like what they're doing right now.far as they've got a great pipeline. a lot of people don't understand that. you look at the trading in a forward p/e of 11, it's very attractive. i look at disney in the same manner, when i look at the management, strong, trades at a fair p/e. if it were to pullback on any kind of a big move in the market and then, of course, i'm always pounding the table on these financials. jpmorgan, that's the standout, the...
90
90
Mar 6, 2013
03/13
by
CNBC
tv
eye 90
favorite 0
quote 0
i think i like amgen more. >> let's talk trash here. >> let's do it. >> call it the dash or trash. lower quality names have led this last bull run. netflix is the best performing stock year to date. mbia, best buy, linkedin as well as zynga. we have said many times on this desk, you stick with what is working. these stocks, this year, have definitely been working. >> well, yeah. let me take mbia. this is a name -- >> hot trade. >> very, very broken and a name that takes us to the teeth of the financial crisis. i would say with the dash for trash, it's all about a stock-specific or special situation. and mbia, law suits against this firm because, effectively, they sequestered -- maybe a nice word to be using these days, they kwarn teed off, they siphoned off a big amount of good assets from this bank and took it away from, essentially, the credit torps, like bank of america, like sockgen. it looks like they are going to win that case, i mean mbia. that's part of the big surge today. it's about the normalization of their balance sheet and taking away some of the liabilities. i think
i think i like amgen more. >> let's talk trash here. >> let's do it. >> call it the dash or trash. lower quality names have led this last bull run. netflix is the best performing stock year to date. mbia, best buy, linkedin as well as zynga. we have said many times on this desk, you stick with what is working. these stocks, this year, have definitely been working. >> well, yeah. let me take mbia. this is a name -- >> hot trade. >> very, very broken and a name...
487
487
Mar 26, 2013
03/13
by
CNBC
tv
eye 487
favorite 0
quote 0
>> amgen worked incredibly well, bristol-mye bristol-myers. on, allergen, close to a 52-week high. take a lack at hrc. that's hill raum. that's a name, small cap type of company in the medical equipment space that i think will continue to move higher. >> i think if you want to be safe, go with the xlv and get a broad swath. you have to dig into what the company does. so for me, i'd much rather be in an xl. >> merck and avid have lagged. i like both of them. we own both of them. bristol-myers is interesting. >> bristol-myers. >> that's right. i'm not going to say that. >> what's interesting about bristol is you're seeing a re-rating. their pooipline is almost li pipeline is like a biotech pipeline. i'd hold on to that one. >>> next up on the "half" not so fast, brian kelly. your turn to show us how to manage a losing trade. we're going to reveal exactly what the stock is, where we think it's heading next. you asked for it on twitter. we're going to deliver. four plays, four stocks. you can make your next move when we come back. [ female announc
>> amgen worked incredibly well, bristol-mye bristol-myers. on, allergen, close to a 52-week high. take a lack at hrc. that's hill raum. that's a name, small cap type of company in the medical equipment space that i think will continue to move higher. >> i think if you want to be safe, go with the xlv and get a broad swath. you have to dig into what the company does. so for me, i'd much rather be in an xl. >> merck and avid have lagged. i like both of them. we own both of...
118
118
tv
eye 118
favorite 0
quote 0
apple, oracle, amgen, southwest airlines, all these new things came along.s to turn us into this mythical west european paradise of stagnation and high unemployment, that spirit is still alive in this country. and if we just make a few changes, in a few years, you will see it really blossom again. stuart: love it. steve forbes, thank you very much. >> thank you. stuart: all right. that was taped friday when i was wearing a different tie. let's call it socialism light, france backs down on its plan to tax millionaires. we will deal with it next. >> meet bill and melissa. like many, they built their financial house on stocks, bonds, and insurance... and then saw it blow away with the first winds of economic change. when mary lost her husband, she invested in real estate. but when the housing bubble burst... so did her financial future. robert and rachel discovered the security, safety, and stability of american bullion, the name you can trust for 401(k) rollovers and i.r.a. transfers. unlike other gold companies, american bullion handles all the paperwork for
apple, oracle, amgen, southwest airlines, all these new things came along.s to turn us into this mythical west european paradise of stagnation and high unemployment, that spirit is still alive in this country. and if we just make a few changes, in a few years, you will see it really blossom again. stuart: love it. steve forbes, thank you very much. >> thank you. stuart: all right. that was taped friday when i was wearing a different tie. let's call it socialism light, france backs down on...